Immunoglobulin amyloidosis (AL) which is characterized by extracellular deposition of fibril complexes composed of monoclonal immunoglobulin light chains (LC) is the most common form of systemic amyloidosis and is generally associated with the worst prognosis. Little is known about the pathogenic mechanisms involved in fibril formation, but two major factors may be involved. One is the synthesis of abnormal protein structure and a second involves defective protein degradation. This proposal seeks to test the hypothesis that the amino acid sequence of Ig LC variable regions plays a determining role in the pathogenesis of AL amyloid. This hypothesis is based on preliminary data of amino acid sequences of amyloid proteins which show unique variations. To test this hypothesis it will be necessary to isolate and determine the primary structure of a number of amyloid proteins and evaluate the effect of these substitutions on secondary and tertiary structure. Amyloid fibrils or their precursors will be isolated by standard methods and subjected to complete amino acid sequence analysis. An important part of these studies will be the selection of appropriate LC proteins for structural analyses. LC proteins, which have already been assigned to subgroups by sequence analysis, will be used to make monoclonal antibodies that are specific for the subgroups that are of interest (e.g. kappa I, lambda I and VI). All LC (amyloid and myeloma) proteins can then be typed so that only those belonging to the desired subgroups will be subjected to complete sequence analysis. In this way immunologic techniques will be used to restrict the chemical studies to a level that can be more easily accomplished. In addition, attempts will be made to identify monoclonal antibodies which recognize amyloid LC but not myeloma LC. The effects of amino acid substitutions on the structure of amyloid LC will be investigated in several ways. 1) Secondary structure analysis using tested prediction models will be used to search for alterations in beta sheet and turn forming potential. 2) Association constants for LC dimers will be determined to identify any increase or decrease in intradimer binding. 3) Computer graphics will be used to identify new intra and intermolecular interactions generated by the amino acid substitutions found in the amyloid subunit proteins. Using these methods we hope to define the mechanisms of amyloid fibril formation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
7R01DK034881-05
Application #
3233150
Study Section
Biochemistry Study Section (BIO)
Project Start
1985-09-23
Project End
1991-08-31
Budget Start
1989-09-01
Budget End
1991-08-31
Support Year
5
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Uemichi, T; Liepnieks, J J; Yamada, T et al. (1996) A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood 87:4197-203
Steiner, R D; Paunio, T; Uemichi, T et al. (1995) Asp187Asn mutation of gelsolin in an American kindred with familial amyloidosis, Finnish type (FAP IV). Hum Genet 95:327-30
Schormann, N; Murrell, J R; Liepnieks, J J et al. (1995) Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc Natl Acad Sci U S A 92:9490-4
Yamada, T; Liepnieks, J J; Kluve-Beckerman, B et al. (1995) Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 41:94-7
Yamada, T; Kluve-Beckerman, B; Liepnieks, J J et al. (1995) In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. Scand J Immunol 41:570-4
Uemichi, T; Gertz, M A; Benson, M D (1994) Amyloid polyneuropathy in two German-American families: a new transthyretin variant (Val 107). J Med Genet 31:416-7
Rosen, H N; Murrell, J R; Liepnieks, J J et al. (1994) Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin's affinity for iodothyronines. Endocrinology 134:27-34
Berni, R; Malpeli, G; Folli, C et al. (1994) The Ile-84-->Ser amino acid substitution in transthyretin interferes with the interaction with plasma retinol-binding protein. J Biol Chem 269:23395-8
Zeldenrust, S R; Murrell, J; Farlow, M et al. (1993) RFLP analysis for APP 717 mutations associated with Alzheimer's disease. J Med Genet 30:476-8
Hamilton, J A; Steinrauf, L K; Braden, B C et al. (1993) The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. J Biol Chem 268:2416-24

Showing the most recent 10 out of 27 publications